BlackRock’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,044,487
| Closed | -$151M | – | 5734 |
|
|
2026
Q1 | $151M | Sell |
7,044,487
-1,793,087
| -20% | -$25.3M | ﹤0.01% | 1847 |
|
|
2025
Q4 | $82.4M | Sell |
8,837,574
-163,881
| -2% | -$1.37M | ﹤0.01% | 2229 |
|
|
2025
Q3 | $63.5M | Sell |
9,001,455
-828,976
| -8% | -$5.7M | ﹤0.01% | 2362 |
|
|
2025
Q2 | $63.9M | Buy |
9,830,431
+3,072,502
| +45% | +$21.1M | ﹤0.01% | 2316 |
|
|
2025
Q1 | $53.6M | Buy |
6,757,929
+602,092
| +10% | +$6.49M | ﹤0.01% | 2343 |
|
|
2024
Q4 | $78M | Buy |
6,155,837
+1,446,675
| +31% | +$20.1M | ﹤0.01% | 2218 |
|
|
2024
Q3 | $65.6M | Buy |
4,709,162
+175,720
| +4% | +$2.51M | ﹤0.01% | 2318 |
|
|
2024
Q2 | $62.5M | Sell |
4,533,442
-497,993
| -10% | -$7.29M | ﹤0.01% | 2286 |
|
|
2024
Q1 | $83.1M | Sell |
5,031,435
-94,636
| -2% | -$1.42M | ﹤0.01% | 2165 |
|
|
2023
Q4 | $74.8M | Buy |
5,126,071
+437,637
| +9% | +$5.31M | ﹤0.01% | 2256 |
|
|
2023
Q3 | $57.5M | Buy |
4,688,434
+1,123,701
| +32% | +$14.7M | ﹤0.01% | 2323 |
|
|
2023
Q2 | $42.6M | Buy |
3,564,733
+1,306,238
| +58% | +$17.1M | ﹤0.01% | 2585 |
|
|
2023
Q1 | $30.2M | Sell |
2,258,495
-176,773
| -7% | -$3.45M | ﹤0.01% | 2755 |
|
|
2022
Q4 | $52.4M | Sell |
2,435,268
-105,967
| -4% | -$2.17M | ﹤0.01% | 2433 |
|
|
2022
Q3 | $50.9M | Buy |
2,541,235
+578,511
| +29% | +$12.3M | ﹤0.01% | 2422 |
|
|
2022
Q2 | $35.1M | Buy |
1,962,724
+799,808
| +69% | +$8.26M | ﹤0.01% | 2732 |
|
|
2022
Q1 | $11.5M | Buy |
1,162,916
+410,797
| +55% | +$5.43M | ﹤0.01% | 3502 |
|
|
2021
Q4 | $12.7M | Buy |
752,119
+230,846
| +44% | +$4.74M | ﹤0.01% | 3526 |
|
|
2021
Q3 | $12.4M | Buy |
521,273
+516,901
| +11,823% | +$12.4M | ﹤0.01% | 3579 |
|
|
2021
Q2 | $99K | Buy |
+4,372
| New | +$91.2K | ﹤0.01% | 5051 |
|
Other funds holding DAWN
BlackRock's DAWN Position: Q2 2026 in Review
BlackRock sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 7,044,487 shares — an estimated $151M sold.
BlackRock first reported a position in DAWN in Q2 2021 and held it in 20 quarters. The position peaked at $151M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- BlackRock reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 7,044,487 Day One Biopharmaceuticals shares in Q2 2026, an estimated $151M.
- BlackRock first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 20 quarters.
- BlackRock's Day One Biopharmaceuticals position peaked at $151M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.